Review



emsa-based elisa kit trans-am stat3  (Active Motif)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Active Motif emsa-based elisa kit trans-am stat3
    A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. <t>and</t> <t>DNA</t> binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by <t>EMSA</t> analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.
    Emsa Based Elisa Kit Trans Am Stat3, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/emsa-based elisa kit trans-am stat3/product/Active Motif
    Average 90 stars, based on 1 article reviews
    emsa-based elisa kit trans-am stat3 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3"

    Article Title: Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3

    Journal: Oncotarget

    doi: 10.18632/oncotarget.13240

    A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. and DNA binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by EMSA analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.
    Figure Legend Snippet: A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. and DNA binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by EMSA analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.

    Techniques Used: Expressing, Activation Assay, Binding Assay, Activity Assay, Western Blot



    Similar Products

    emsa-based elisa kit trans-am stat3  (Active Motif)
    90
    Active Motif emsa-based elisa kit trans-am stat3
    A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. <t>and</t> <t>DNA</t> binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by <t>EMSA</t> analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.
    Emsa Based Elisa Kit Trans Am Stat3, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/emsa-based elisa kit trans-am stat3/product/Active Motif
    Average 90 stars, based on 1 article reviews
    emsa-based elisa kit trans-am stat3 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. and DNA binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by EMSA analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.

    Journal: Oncotarget

    Article Title: Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3

    doi: 10.18632/oncotarget.13240

    Figure Lengend Snippet: A. STAT3 inhibitor decreased lung cancer-mediated IL-10 expression. Laricitrin inhibited lung cancer-mediated upregulation on STAT3 activation B. and DNA binding activity C. in monocytes. Laricitrin inhibited LPS-mediated upregulation on STAT3 activation D. and DNA binding activity E. in monocytes. CD14 + monocytes were pretreated with laricitrin (2 μM) for 1 h, and then A549, CL1-5-CM or LPS (100 ng/ml) added for 30 min. The phosphorylation of STAT3 was assessed by immunoblot. The DNA binding activity of STAT3 was assessed by EMSA analysis. All results are representative of at least three independent experiments, and each value is the mean ± SD of three determinations. *p<0.05, **p<0.01, ***p<0.001.

    Article Snippet: The DNA binding activity of STAT3 transcription factor was examined using EMSA-based ELISA kits (Trans-AM STAT3 kit, Active Motif ® , Carlsbad, CA, USA).

    Techniques: Expressing, Activation Assay, Binding Assay, Activity Assay, Western Blot